Advertisement
Screener

Arcus Biosciences, Inc. (RCUS) ROA

Arcus Biosciences, Inc. ROA

Return on assets (ROA) is the profit a company earns for every dollar of assets it uses, shown as a percentage. It is net income divided by total assets, and the table shows both amounts. Because assets are funded by lenders as well as shareholders, ROA is not inflated by borrowing the way ROE can be, and it is naturally lower for businesses that need many factories, stores or other assets. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Arcus Biosciences, Inc. roa for the quarter ending 2026-06-30 was -49.78%, a change of -22.06% year-over-year.
  • Arcus Biosciences, Inc. roa for the quarter ending 2026-03-31 was -37.01%, a change of -3.19% year-over-year.
  • Arcus Biosciences, Inc. roa for the quarter ending 2025-12-31 was -30.99%, a change of -6.38% year-over-year.
  • Arcus Biosciences, Inc. roa for the quarter ending 2025-09-30 was -35.01%, a change of -13.44% year-over-year.
  • Arcus Biosciences, Inc. roa for fiscal 2025 was -30.99%, a change of -6.38% from fiscal 2024.
  • Arcus Biosciences, Inc. roa for fiscal 2024 was -24.61%, a change of 3.43% from fiscal 2023.
  • Arcus Biosciences, Inc. roa for fiscal 2023 was -28.04%, a change of -8.19% from fiscal 2022.
  • Arcus Biosciences, Inc. roa for fiscal 2022 was -19.85%, a 696.29% decline from fiscal 2021.
Available history
2017-12-31 to 2026-06-30
Data captured

Historical ROA

DateROANet income 12 monthNet income 3 monthTotal assets
2026-06-30-49.78%-$460M-$91.00M$924M
2026-03-31-37.01%-$369M-$128.00M$997M
2025-12-31-30.99%-$353M-$106.00M$1.14B
2025-09-30-35.01%-$341M-$135.00M$974M
2025-06-30-27.72%-$298M$0.00$1.08B
2025-03-31-33.82%-$391M-$112.00M$1.16B
2024-12-31-24.61%-$283M-$94.00M$1.15B
2024-09-30-21.57%-$270M-$92.00M$1.25B
2024-06-30-20.99%-$249M-$93.00M$1.19B
2024-03-31-17.87%-$231M-$4.00M$1.29B
2023-12-31-28.04%-$307M-$81.00M$1.1B
2023-09-30-24.60%-$293M-$71.00M$1.19B
2023-06-30-23.52%-$287M-$75.00M$1.22B
2023-03-31-22.25%-$279M-$80.00M$1.25B
2022-12-31-19.85%-$267M-$67.00M$1.35B
2022-09-305.71%$79.54M-$65.00M$1.39B
2022-06-304.51%$66.56M-$67.00M$1.48B
2022-03-313.73%$57.59M-$68.00M$1.54B
2021-12-313.33%$53M$279.54M$1.59B
2021-09-30-33.19%-$278.53M-$77.97M$839.29M
2021-06-30-22.11%-$198.74M-$75.97M$898.77M
2021-03-31-17.95%-$167.84M-$72.59M$935.12M
2020-12-31-15.93%-$123M-$51.85M$772.29M
2020-09-30-10.80%-$87.6M$1.82M$811.08M
2020-06-30-23.22%-$111.78M-$45.07M$481.39M
2020-03-31-53.82%-$94.79M-$27.75M$176.14M
2019-12-31-41.71%-$84.71M-$16.60M$203.11M
2019-09-30-37.06%-$80.41M-$22.35M$216.96M
2019-06-30-28.82%-$68.87M-$28.09M$238.97M
2019-03-31-21.01%-$54.31M-$17.67M$258.53M
2018-12-31-18.04%-$49.6M-$12.29M$274.93M
2018-09-30-17.62%-$50.51M-$10.81M$286.72M
2018-06-30-21.38%-$62.82M-$13.53M$293.87M
2018-03-31-19.27%-$58.84M-$12.95M$305.4M
2017-12-31-27.87%-$53.08M-$13.21M$190.49M

Annual ROA

DateROANet income 12 monthTotal assets
2025-12-31-30.99%-$353M$1.14B
2024-12-31-24.61%-$283M$1.15B
2023-12-31-28.04%-$307M$1.1B
2022-12-31-19.85%-$267M$1.35B
2021-12-313.33%$53M$1.59B
2020-12-31-15.93%-$123M$772.29M
2019-12-31-41.71%-$84.71M$203.11M
2018-12-31-18.04%-$49.59M$274.93M
2017-12-31-27.87%-$53.08M$190.49M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Dyne Therapeutics, Inc. (DYN)United States$3.084B-7.09
Arcutis Biotherapeutics, Inc. (ARQT)United States$3.303B115.47
Enliven Therapeutics, Inc. (ELVN)United States$3.307B-35.07
Amylyx Pharmaceuticals, Inc. (AMLX)United States$3.361B-13.15
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
Organon & Co. (OGN)United States$3.603B17.03
PRECIGEN, INC. (PGEN)United States$2.757B-12.94
NewAmsterdam Pharma Co N.V. (NAMS)$2.719B-15.37
Xenon Pharmaceuticals Inc. (XENE)$3.684B-14.27
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36